Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies (Details Textual)

v3.20.2
Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies (Details Textual)
$ in Thousands, shares in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
USD ($)
shares
Sep. 30, 2019
shares
Sep. 30, 2020
USD ($)
shares
Sep. 30, 2019
shares
Dec. 31, 2019
USD ($)
Number of Operating Segments     1    
Retained Earnings (Accumulated Deficit), Ending Balance $ (54,277)   $ (54,277)   $ (39,561)
Impairment of Intangible Assets (Excluding Goodwill), Total     0   0
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance $ 400   $ 400   300
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 22.9 14.7 20.8 11.3  
Annamycin [Member]          
Vendor Prepayments and Deposits, Expansion of Production Commitments $ 1,100   $ 1,100   $ 1,500